文献速递免疫规划

基于人细小病毒病毒样颗粒的多表位HIV-1疫苗的设计与评价

Design and evaluation of a multi-epitope HIV-1 vaccine based on human parvovirus virus-like particles.
PubMed 文献 · Vaccine · 2024-12-24

本研究以B19人细小病毒病毒样颗粒(VLP)为载体展示多个HIV-1表位,构建嵌合VLP-MHIV-A,经动态光散射和透射电镜确认组装与形态,HIV阳性患者血清确认抗原性;雌性C57bl/6小鼠经肌内或皮下免疫后,两条途径均诱导针对全VLP的血清和阴道洗液抗体及针对CD4结合位点、V3环和gp41表位的抗体,两途径均有中和活性,肌内途径更有效,对1型B亚型病毒感染抑制最高达50%。

要点

  • B19人细小病毒VLP可展示多个HIV-1表位并组装为嵌合VLP-MHIV-A。
  • HIV阳性患者血清可与嵌合VLP-MHIV-A结合,确认抗原性。
  • 雌性C57bl/6小鼠肌内或皮下免疫均诱导体液和细胞应答及中和活性。

核心结论

  • 嵌合VLP是能诱导具有中和活性的HIV-1特异性抗体的有效抗原。

研究设计与样本

  • 以B19人细小病毒VLP为载体展示多个HIV-1表位构建嵌合VLP-MHIV-A。
  • 用动态光散射确认完整衣壳组装,用透射电镜确认形态。
  • 用HIV阳性患者血清结合实验确认抗原性。
  • 雌性C57bl/6小鼠经肌内或皮下途径免疫,评估特异性体液和细胞应答,并用体外报告细胞系统测定中和活性。

主要发现

  • 两种免疫途径均在血清和阴道洗液中诱导针对全VLP的 substantial 抗体。
  • 检测到针对CD4结合位点、V3环和gp41若干表位的抗体应答。
  • 两种免疫途径均显示中和活性,肌内途径更有效,对1型B亚型病毒感染抑制最高达50%。

关键数值与推荐

  • 表位基于其作为患者中广谱中和抗体(bnAbs)结合位点而选择。
  • 肌内途径对1型B亚型病毒感染抑制最高达50%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of a protective HIV vaccine remains a challenge given the high antigenic diversity and mutational rate of the virus, which leads to viral escape and establishment of reservoirs in the host. Modern antigen design can guide immune responses towards conserved sites, consensus sequences or normally subdominant epitopes, thus enabling the development of broadly neutralizing antibodies and polyfunctional lymphocyte responses. Conventional epitope vaccines can often be impaired by low immunogenicity, a limitation that may be overcome by using a carrier system. In this work, Virus-Like Particles (VLPs) of the B19 human parvovirus were used as a carrier system for multiple HIV-1 epitopes displayed on the surface. Epitopes were selected based on being the binding site of broadly neutralizing antibodies (bnAbs) in patients. Full capsid assembly was confirmed by dynamic light scattering and morphology was confirmed by transmission electron imaging. The resulting chimeric VLPs were termed "VLP-MHIV-A". Antigenicity was confirmed by HIV+ patient sera binding to the chimeric VLP-MHIV-A. To evaluate immunogenicity, female C57bl/6 mice were immunized with the chimeric VLPs either via the intramuscular or subcutaneous route, specific humoral and cellular responses were evaluated, and neutralizing activity was measured in an in vitro reporter cell system. Substantial antibodies against whole-VLPs were induced in serum and vaginal lavages for both immunization routes. Antibody responses against the CD4 binding site, V3 loop and several epitopes of gp41 were detected. Both immunization routes demonstrated neutralizing activity; however, the I.M. route was more effective, showing significant neutralizing activity with up to 50 % inhibition of a tier 1 clade B virus infection. Taken as a whole, these results show that chimeric VLPs are an effective antigen capable of inducing HIV-1 specific antibodies with neutralizing activity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Pérez-Saucedo D, Castro-Perea NV, Ruíz-Cruz A, et al. Design and evaluation of a multi-epitope HIV-1 vaccine based on human parvovirus virus-like particles. Vaccine. 2024. PMID: 39721354. doi:10.1016/j.vaccine.2024.126663

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。